Shares of Mesoblast limited (NASDAQ:MESO) have been assigned an average recommendation of “Buy” from the eight analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $11.92.
A number of research firms recently weighed in on MESO. Zacks Investment Research raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Saturday, February 2nd. HC Wainwright reaffirmed a “buy” rating and set a $6.50 price objective on shares of Mesoblast in a research report on Thursday, January 31st. ValuEngine cut shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th. Oppenheimer set a $15.00 price objective on shares of Mesoblast and gave the stock a “buy” rating in a research report on Thursday, December 13th. Finally, TheStreet cut shares of Mesoblast from a “c-” rating to a “d+” rating in a research report on Monday, December 10th.
Several large investors have recently bought and sold shares of the stock. Capital World Investors purchased a new position in Mesoblast in the 3rd quarter valued at approximately $3,695,000. Penbrook Management LLC raised its holdings in shares of Mesoblast by 6.2% in the 4th quarter. Penbrook Management LLC now owns 240,900 shares of the company’s stock valued at $993,000 after purchasing an additional 14,000 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Mesoblast by 249.8% in the 3rd quarter. Renaissance Technologies LLC now owns 165,161 shares of the company’s stock valued at $1,348,000 after purchasing an additional 117,951 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Mesoblast in the 3rd quarter valued at $215,000. Finally, Jane Street Group LLC acquired a new stake in shares of Mesoblast in the 3rd quarter valued at $117,000. 3.01% of the stock is owned by hedge funds and other institutional investors.
Mesoblast (NASDAQ:MESO) last posted its quarterly earnings data on Thursday, November 15th. The company reported ($0.20) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.04. The firm had revenue of $11.64 million during the quarter, compared to analysts’ expectations of $1.03 million. Mesoblast had a negative net margin of 171.79% and a negative return on equity of 12.90%. On average, sell-side analysts expect that Mesoblast will post -0.93 EPS for the current fiscal year.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Featured Story: Average Daily Trade Volume – What You Need to Know
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.